Mozafari, P., Ibrahim, S. A., Pawar, A. A., Ali, Z. I. O., & Nair, A. S. (2026). Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk during Extended Ocrelizumab Therapy in Multiple Sclerosis. Junior Researchers, 4(2), 57–69. https://doi.org/10.52340/jr.2026.04.02.04